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Dopaminergic neurotransmission mediates a majority of the vital central nervous system
functions. Disruption of these synaptic events provokes a multitude of neurological
pathologies, including Parkinson’s, schizophrenia, depression, and addiction. Growing
evidence supports a key role for noncoding RNA (ncRNA) regulation in the synapse.
This review will discuss the role of both short and long ncRNAs in dopamine signaling,
including bioinformatic examination of the pathways they target. Specifically, we focus
on the contribution of ncRNAs to dopaminergic dysfunction in neurodegenerative as well
as psychiatric disease.
Keywords:microRNAs, psychiatric, neurodegeneration, noncoding RNA, dopaminergic, schizophrenia, dopamine,
epigenetic
INTRODUCTION
Dopamine is a potent neurotransmitter in the central nervous system that governs a diverse
panel of neuronal functions. Accumulating studies indicate that noncoding RNAs (ncRNAs)
modulate almost all aspects of dopamine signaling, including its receptors, and transporter, as
well as differentiation and viability of dopaminergic neurons. The processing and transcription
of those implicated ncRNAs are also subject to control. Moreover, there are emerging roles for both
short and long ncRNAs (lncRNAs) in synaptic transmission, including miRNAs, and antisense
transcripts. This review discusses ncRNA-mediated mechanisms which influence dopaminergic
signaling under control and pathogenic conditions.
The diverse classes of ncRNAs target all stages in the lineage from stem cells to mature
dopaminoceptive neurons (DN) which express dopamine receptors. One of the first ncRNAs
reported to modulate midbrain DN (mDN) differentiation and viability was miR-133b (Kim et al.,
2007). A subset of additional miRNAs are also now known to direct DN fate, including miR-132,
miR-135a2, and miR-218 (Yang et al., 2012; Anderegg et al., 2013; Baek et al., 2014). Moreover,
studies indicate that selected miRNAs, such as miR-132, influence DN maturation, and survival
by binding to key neuronal transcription factors, including Nurr1 (Yang et al., 2012). Reports
also suggest that miRNA processor genes, such as Dicer, are required for terminal differentiation
of embryonic stem cells (ESC) into DN (Kim et al., 2007). Dicer cleaves the mature miRNA
from its precursor transcript. Mouse studies revealed that Dicer depletion in dopaminoceptive
neurons alters brain morphology and neurobehavioral patterns (Cuellar et al., 2008). Further,
ablation of Dicer in mouse mDN led to nearly 90% cell death by 8 weeks of age; however, that
level of degeneration was not seen when Dicer was depleted in neurons receiving input from
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dopamine-transporter expressing cells (Kim et al., 2007). These
data suggest that miRNA processing deficits may impact specific
classes of mature neurons more potently.
It is now evident that ncRNAs target expression of the
receptors which bind dopamine. There are at least 5 reported
subtypes of dopamine receptors (D1R-D5R), however, D1R,
and D2R are the most abundant (Greengard, 2001; Girault
and Greengard, 2004). Protein levels of D1R and D2R are
well known to fluctuate during the normal aging process as
well as in numerous neuronal pathologies (Hurley et al., 2001,
2003; Kaasinen and Rinne, 2002; Rangel-Barajas et al., 2015).
In vitro analysis of varying deletion constructs for the D1R
gene identified regions of putative miRNA binding sites within
the D1R 3′UTR. It was discovered that a short 94 bp segment
of the 3′UTR was adequate for post-transcriptional regulation
and contains a miR-142-3p binding site (Tobón et al., 2012).
Correspondingly, similar studies have also investigated ncRNA
control of D2R. Antisense-knockdown of neuronally-enriched
miR-9 and miR-326 provoked upregulated expression of D2R
3′UTR in luciferase based assays (Shi et al., 2014). It is important
to note, however, that D1R and D2R pathways are also intricately
connected and their receptors can even form heteromers (Hasbi
et al., 2009; Perreault et al., 2011a,b, 2014a,b). Thus, a subset of
ncRNAs may influence signaling of multiple receptor types.
It is well established that dopamine receptor signaling is
synchronized with excitatory and inhibitory responses triggered
by other neurotransmitters. The role of ncRNAs inmediating this
cross-talk, however, is undefined. Saba et al suggests miR-181a as
a candidate with a pleiotropic role in neurotransmission, as its
expression is modulated by dopamine while it also targets the
glutamate receptor subunit GluA2 (Saba et al., 2012). Notably,
glutamatergic transmission emerges through AMPA, Kainate,
NMDA, and metabotropic receptor classes, underscoring the
complexity of synaptic physiology (Planells-Cases et al., 2006).
Orchestration of this extensive neurotransmission network by
ncRNAs may reveal enduring mechanistic questions that have
stymied drug development for many neurological pathologies.
Dopamine signaling is ubiquitous throughout the brain,
however, this pathway also functions in select tissues outside of
the central nervous system, including the cardiovascular system
and kidney (Lokhandwala and Barrett, 1982; Lokhandwala and
Amenta, 1991). Impaired dopamine-signaling in the kidney is a
primary contributor to hypertension (Banday and Lokhandwala,
2008; Chugh et al., 2012, 2013). Correspondingly, hypertension
is repeatedly linked to neuronal dysfunction, including cognitive
deficits in patients with Alzheimer’s Disease. Investigating
ncRNA regulation of dopamine-mediated hypertension in the
kidney could reveal novel origins of neurological disease. A
recent study identified five dysregulated miRNAs in renal cells
from patients carrying hypertension-associated polymorphisms
(SNP) in the D2R gene (Han et al., 2015). Of those 5
misregulated miRNAs in the SNP-DR2 cells, miR-217 expression
was directly connected to D2R expression through a TGF
β1-Wnt5a-Ror2 feedback loop. In a separate study, Zhang
et found that let-7d silenced dopamine-receptor 3 (D3R) in
renal cells at the chromatin level through histone-3 –lysine-9
dimethylation (Zhang et al., 2016). However, these studies did
not explore whether specific disruption of these miRNAs induce
hypertension and associated neuronal damage.
This review focuses on neuronal ncRNA mediators of
dopamine signaling, although, it is evident this epigenetic
pathway also exerts significant influence in other cell types.
We outline a subset of these ncRNAs which are implicated in
neurodegenerative and neuropsychiatric pathologies Table 1).
Additionally, we bioinformatically examined the pathways
targeted by the reported miRNAs. Using Ingenuity Pathway
Analysis (IPA), several key dopamine-associated pathways were
identified, including Dopamine-DARPP32 in cAMP Signaling,
Dopamine Receptor Signaling, Synaptic LTP/LTD, CREB Signaling
in Neurons, andAxon Guidance Signaling (Figure 1). Overall, the
published findings suggest the entire neurotransmission cascade
activated by dopamine, as well as its misregulation, is guided by
ncRNAs.
miRNA-MEDIATED REGULATION OF
DOPAMINE SIGNALING IN
NEUROLOGICAL DISEASE
Dopamine Receptors and miRNAs in
Neurological Disease
All five classes of dopamine receptors are putative miRNA
targets in neurological pathologies, although D1R and D2R are
the most interrogated to date. In neurodegenerative Parkinson’s
Disease (PD), these patients classically display upregulated
expression of D1R and D2R with hypersensitive response
to dopamine (Seeman and Niznik, 1990; Kaasinen et al.,
2000; Hurley et al., 2001; Gerfen et al., 2002; Zhu et al.,
2002; Chu et al., 2004; Hisahara and Shimohama, 2011).
Studies by Tan et al revealed that genetic knockout of miR-
128 in D1-neurons of wild-type (WT) mice enhances D1R-
activation by a dopamine agonist and provokes increased
ERK2 expression (Tan et al., 2013). Parallel responses of
D1R-hyperexcitablity/ERK2 in miR-128 deficient mice and PD
patients suggests this miRNA is an active mechanism underlying
PD pathology. In a separate study, a drosophila model which
recapitulates PD through common genetic variants of alpha-
synuclein uncovered a dysfunctional D2R-miR-137 pathway
(Kong et al., 2015). Expression of miR-137 was elevated in
the PD drosophila and anti-correlated with D2R protein levels,
consistent with miRNA target regulation. Subsequently, miR-137
binding sites in the D2R gene were validated through in vitro
analyses.
Targeting of dopamine receptor signaling by physiological
stressors that trigger depression and related neuropsychiatric
phenotypes is guided by select miRNAs (Zhang et al., 2013, 2015).
Early life stress (ELS) can broadly impact normal development
of the dopamine system, leading to inadequate coping methods
for chronic-unpredictable stress (CUS) and depression in adults.
Expression profiles of D1R, miR-504 (a D1R target), and D2R
were explored in rats with ELS modeled through maternal
deprivation (MD) coupled with exposure to CUS at mature
age (MD/CUS) (Zhang et al., 2013). The MD/CUS rats indeed
showed significant correlation between D1R, D2R, miR-504 as
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TABLE 1 | Dopamine-responsive miRNAs and their association with neurological functions/disease.
Component of Dopamine pathway
targeted by miRNA
miRNA (or miRNA
processor) implicated
Disease (or function) miRNA is associated with References
Dopaminergic neuronal development miRs–132, 133b, 135a2,
218; Dicer
differentiation and viability of dopaminergic neurons Kim et al., 2007
D1R (dopamine-1-receptor) miR-142-3p binds D1R 3′UTR Tobón et al., 2012
miR-128 Parkinson’s Disease (with ERK2 regulatory loop) Tan et al., 2013
miR-382 alcohol addiction Li J. et al., 2013
miR-504 (1) polymorphism in miRNA binding site linked to nicotine
addiction (2) depression
(1) Huang and Li, 2009
(2) Zhang et al., 2013
D2R (dopamine-2-receptor) miR-9 and miR-326 (1) Binds D2R 3′UTR (2) depression (1) Shi et al., 2014 (2) Zhang
et al., 2015
miR-137 Parkinson’s Disease Kong et al., 2015
miR-217 Regulates D2R in kidney; polymorphism in miRNA binding
site linked to hypertension
Han et al., 2015
Ago2 (Argonaute 2) Cocaine addiction Schaefer et al., 2010
Dgcr8 22q11 deletion syndrome/schizophrenia Chun et al., 2014
D3R Let-7d Binds D3R 3′UTR (kidney) Zhang et al., 2016
DAT (dopamine transporter) miRs-30b-5p, 1301, 1972,
6070
miRNA binding sites located in polymorphic region
associated with Attention Deficit Hyperactivity Disorder
Sery et al., 2015
miRs-762, 1266, 3127,
3192, 4259
miRNA binding sites located in polymorphic region
associated with Bipolar Disorder
Pinsonneault et al., 2011
Neurotransmitter signaling crosstalk miR-181a Crosstalk between dopamine and AMPA signaling Saba et al., 2012
Dopaminergic neuronal markers (i.e.
Nurr1, TH, Pitx3)
Ago2 Morphine administration - dysregulates a regulatory loop of;
Ago2, Nurr1, Pitx3 and TH, and miR-133b
Sanchez-Simon et al., 2010
miR-133b Parkinson’s Disease -regulatory loop with miR-133b and Pitx3 Kim et al., 2007
schizophrenia- regulatory loop with miR-133b, Nurr1, Pitx3,
TH, and D1R
Song et al., 2012
cocaine addiction –regulatory with miR-133b, Pitx3, TH, and
D1R/D2R
Barreto-Valer et al., 2012
well as correlation of D2R and miR-504 with depression-related
behaviors. In a separate study also conducted by Zhang et al.
they subsequently identified several miRNAs (miR-9, miR-200a,
miR-141, andmiR-326) that target the 3′-UTR of the D2R (Zhang
et al., 2015). In vitro analyses confirmed that miR-9 binds the
D2R transcript (Zhang et al., 2015). They also found that miR-9,
miR-326, and D2R correlated with depressive-like phenotypes
in mature MD/CUS rats. In addition, aberrant expression
of miR-326 in the MD/CUS rats was normalized with the
anti-depressant escitalopram (Zhang et al., 2015). These results
not only implicate dopamine-regulated miRNAs in depression,
but also suggests these ncRNAs may mediate treatment response
to anti-depressants.
Targeting of dopamine receptors by miRNAs was also
uncovered in a model for addiction (Li J. et al., 2013).
Post-administration of alcohol to rats, the NAc in the basal
forebrain displayed repressed levels of miR-382 levels while its
bioinformatic target, D1R, was upregulated. Cell-based studies
as well as site-specific knockdown and overexpression of miR-
382 in rat NAc confirmed it targets the D1R gene (Li J. et al.,
2013). Moreover, miR-382 overexpression altered the neuronal
excitability responses of D1R and diminished desire to consume
alcohol. This reportmakes the direct connection betweenmiRNA
regulation of D1R and neuropsychiatric phenotypes in an animal
model.
Disease-associated polymorphic regions in the dopamine
receptor genes can impact miRNA binding to their target sites.
One such reported example is the D1R rs686 polymorphism
linked to nicotine dependence (Huang and Li, 2009). Two
miRNA sites were bioinformatically identified within the rs686
region, miR-504 and miR-296. Further, miR-504 regulation of
D1R was confirmed in vitro. Notably, miR-504 appears to exhibit
stronger binding potential to the rs686 allele compared to the
wild-type (WT) allele, which could alter the allelic representation
of DR1.
Dopamine Transporter (DAT) and miRNAs
in Neurological Disease
The dopamine transporter gene (DAT/SLC6A3) is critical for
removal of dopamine in the synapse to halt neurotransmission
(German et al., 2015; McHugh and Buckley, 2015).
Correspondingly, the disruption of this gene reportedly
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FIGURE 1 | Dopaminergic miRNA nodes in a rich network of connections in synaptic plasticity pathways. Ingenuity pathway analysis (IPA) was used to
explore the molecular connectivity predicted between miRNA implicated in dopaminergic development, function and disease (references for all implicated miRNAs
examined in this figure are listed in Table 1). miRNA targets, both experimentally validated and predicted by TargetScan were filtered with respect to
dopamine-associated canonical pathways and used to generate a network graph. Core miRNA nodes near the center of the graph are color-coded and have colored
edges to denote their connections. The largest network defined by the filter was Dopamine-DARPP32 in cAMP Signaling (85 genes) followed by Dopamine Receptor
Signaling (40). These networks were also enriched with synaptic plasticity pathways, Synaptic LTP/LTD (43/29 genes), CREB Signaling in Neurons (43 genes), and the
Axon Guidance Signaling (27 genes).
provokes numerous distinct neuronal pathologies (German
et al., 2015; McHugh and Buckley, 2015). Two separate studies
investigated miRNA binding in polymorphic regions of the DAT
gene. One study examined a 40-base pair 3′UTR region within
the DAT transcript linked to Attention Deficit Hyperactivity
Disorder (ADHD) (Sery et al., 2015). Bioinformatic analysis of
this 40-base pair segment identified putative sites for miRs-1972,
30b-5p, 1301, and 6070 (Sery et al., 2015). A second study
focused on a DAT polymorphism linked to bipolar disease,
rs27072 (Pinsonneault et al., 2011). The rs27072 analysis
revealed binding sequences for miRs-762, 4259, 3192, 3127,
and 1266 (Pinsonneault et al., 2011). Collectively, although
these findings are only predictive at this point, they provide a
framework for future investigation.
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In addition to dopamine, DAT can also transport
the neurotoxin 6-hydroxydopamine (6-OHDA), eliciting
phenotypes which recapitulate PD (Westerlund et al., 2010).
6-OHDA kills dopaminergic neurons, providing a platform
to identify and study dopamine-regulated ncRNAs. A subset
of miRNAs are reported to mediate 6-OHDA neuronal
damage, including miRs-124, 126, 668-3p, let-7d-3p, 3077-
3p, 665-5p, 99b-3p, 323-3p, 875, 207, 425-5p, 19b-3p, and
338-3p (Li L. et al., 2013; Kim et al., 2014; Saraiva et al.,
2016).
Dopamine Signaling and miRNA
Processing Machinery in Neurological
Disease
The processing of miRNAs involves several stages, and their
disruption is pathogenic (Kocerha et al., 2009, 2015; Chan
and Kocerha, 2012; Chun et al., 2014). The primary-miRNA
is cleaved by Dgcr8 and Drosha, followed by second cleavage
with Dicer into the mature transcript (Bartel, 2004, 2009; Macias
et al., 2013). The mature miRNA gets assembled, along with
argonaute proteins, into RISC for target gene regulation (Bartel,
2004, 2009). Studies by Schaefer et al found that deficiency
of the RISC-associated Argonaute 2 (Ago2) protein in D2R-
neurons significantly reduced self-administration of cocaine in
mice (Schaefer et al., 2010). This Ago2 mouse model was then
used to compile a list of D2R-localized miRNAs which putatively
control cocaine addiction.
Ago2 expression is also reportedly regulated by the pain
medication morphine (García-Pérez et al., 2013). Acute
administration of morphine in rats led to increased Ago2 levels
as well as the disruption of a panel of dopaminergic markers such
as Nurr1, Pitx3, and TH activity. Pitx3 and TH are mentioned
below as part of a conserved miRNA mechanism with miR-133b
in neurological disease. Notably, pain relief is mediated by
dopamine release in the midbrain, a region where miR-133b
functions are reported (Kim et al., 2007; Navratilova et al., 2015).
Indeed, a separate study revealed morphine alters miR133b-Pitx3
expression and differentiation of dopaminergic neurons in a
zebrafish model (Sanchez-Simon et al., 2010). These results
suggest ncRNAs which are regulated by morphine influence
neurotransmission.
The gene for the core miRNA processor, Dgcr8, is located
within the 22ql1 chromosomal locus, a region persistently
associated with schizophrenia and other neurological
anomalies (Merico et al., 2015; Zhao et al., 2015). Studies
by Chun et al showed that a mouse model for the 22q11
deletion impedes Dgcr8 function, leading to enhanced
expression of D2R, and disruption of corticothalamic
synaptic transmission (Chun et al., 2014). Moreover, the
aberrant D2R signaling provokes a hypersensitive response to
antipsychotics used for schizophrenia treatment. Identifying
the specific miRNAs impacted by haploinsufficient Dgcr8
processing in the 22q11 mice would facilitate future
studies. Importantly, these data also suggest ncRNA
mechanisms can influence drug efficacy and medical
outcomes.
Conserved Dopamine-Mediated miRNA
Mechanisms in Disease; the
miR-133b-Pitx3 Example
A shared characteristic of many neurological diagnoses is
impaired synaptic transmission; thus, it is pertinent to uncover
conserved dopamine-linked ncRNA mechanisms in brain
pathologies (Henstridge et al., 2016). One conserved ncRNA
pathway was identified through miRNA expression profiles of
midbrain dopamine neurons (mDNs) in PD patients (Kim et al.,
2007; Briggs et al., 2015). One of the dysregulated miRNAs, miR-
133b, controls mDN differentiation through a feedback loop with
Pitx3 (Kim et al., 2007). Pitx3 is a transcription factor essential for
DN survival (Bergman et al., 2010). A separate study, however,
reported that miR-133b expression is not impacted within the
substantia nigra region of the midbrain (Schlaudraff et al.,
2014). These results suggest the presence of site-specific miRNA
mechanisms, providing an additional layer of dopaminergic
influence.
The Pitx3-miR-133b pathway associated with PD is also
implicated in the neuropsychiatric disorder schizophrenia. Song
et al reported that Pitx3-miR-133b is dysregulated in mice with
schizophrenia phenotypes provoked through overexpression of
the stress protein heme-oxygenase-1 (HO-1) (Song et al., 2012).
Moreover, these mice exhibit disrupted profiles of dopaminergic
markers D1R, Nurr1 and tyrosine hydroxylase (TH), as well
as neurotransmitters serotonin and dopamine. Parallel changes
of dopamine and serotonin in this model is consistent with
extensive cross-talk reported in synaptic signaling (Henstridge
et al., 2016). Further, an independent study found this miRNA
pathway is altered in another neuropsychiatric disorder, cocaine
addiction (Barreto-Valer et al., 2012). Zebrafish embryos were
exposed to cocaine followed by gene expression analysis at
various developmental timepoints. In addition to dysregulated
levels of miR-133b, Pitx3, D1R, TH in these embryos, there
were also significant changes in D2R (Barreto-Valer et al., 2012).
Collectively, these data suggest subsets of epigenetic mechanisms
are conserved across neurological diseases and, further, may
contribute to a general trend of synaptic dysfunction in these
pathologies.
lncRNA REGULATION OF DOPAMINE
SIGNALING IN THE BRAIN
Although miRNAs are the most studied to date, the detection
of neuronal lncRNAs is expanding. One of the first annotated
lncRNAs in the central nervous system, BC1, mediates D2R
expression in vivo and related electrophysiological responses
(Wang et al., 2002; Centonze et al., 2007; Zhong et al.,
2009; Maccarrone et al., 2010). BC1 knockout mice displayed
significant upregulation of D2R protein in the striatum and
potentiated responses to D2R agonists (Centonze et al., 2007).
Moreover, although BC1 was reported to act as a translational
repressor, that is not the mechanism in which it regulates
D2R (Wang et al., 2002; Centonze et al., 2007). This study
suggests BC1 may have additional functions that have yet to be
investigated.
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Recently, Carrieri et al showed that a lncRNA antisense
to the Uchl1 gene (AS-Uchl1) is significantly repressed in
dopaminergic neurons of PD models (Carrieri et al., 2015). The
AS-Uchl1 gene is regulated by Nurr1, a core transcription factor
involved in the maturation and viability of dopamine neurons
(Carrieri et al., 2015). Furthermore, the AS-Uchl1/PARK5 locus
is linked to certain populations of PD patients, suggesting
an intricate regulatory loop between dopamine-responsive
lncRNAs and disease susceptibility genes (Belin and Westerlund,
2008).
Neurodegeneration may also be controlled by lncRNAs
encoded within viral transcripts. Kuan et al showed that p137,
a ncRNA transcribed from the human cytomegaloviral β2.7
gene, is neuroprotective against OHDA-induced cell damage
(Kuan et al., 2012). Compellingly, p137 prevented progression
of PD phenotypes within dopaminergic neurons for both
in vitro and in vivo OHDA models. In addition to the miRNAs
discussed previously, these data suggest that a diverse range of
ncRNA classes influence neurodegenerative pathways. It is also
likely these ncRNAs may regulate each other through feedback
loops.
Investigation of midbrain dopamine neurons (mDN), which
are primary responders to drugs of abuse, revealed lncRNA
modulators of addiction phenotypes (Bannon et al., 2015).
Bannon et al identified a subset of dysregulated lncRNAs inmDN
from post-mortem tissue of cocaine addicts (Bannon et al., 2015).
One of those misregulated lncRNAs is an antisense transcript
to the gene for tumor necrosis factor receptor-associated factor
3-interacting protein 2 (TRAF3IP2). The antisense RNA was
localized to the nucleus of the neurons compared to the
global cellular distribution of TRAF3IP2, suggestive of epigenetic
control at the chromatin level.
A recent report now also suggests Gomafu, a schizophrenia
associated lncRNA, modulates dopaminergic transmission (Ip
et al., 2016). In Gomafu knockout (KO) mice, a significant
increase in dopamine levels was detected in the brain
after exposure to the psychostimulant methamphetamine
(MAP). Notably, the increased dopamine was correlated with
hyperactivity of the KO mice, as measured by open field
and light-dark transition tests (Ip et al., 2016). This study
directly links lncRNA regulation of dopamine signaling with
neurobehavioral phenotypes, although the precise mechanism is
not yet elucidated.
CONCLUSION
Epigenetic regulation of dopamine signaling by ncRNAs is
a vital component to neuronal homeostasis. Correspondingly,
impaired dopaminergic transmission provokes a range of
cognitive, motor, and behavioral phenotypes in CNS disorders.
The untapped pharmacological potential of ncRNA modulators
to normalize aberrant synaptic transmission provides a wide-
open opportunity for drug discovery efforts. Furthermore,
as the dopamine pathway is extensive and partially driven
by undefined mechanisms, the pleiotropic capacity of many
implicated ncRNAs may enhance their efficacy.
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